Filing Details
- Accession Number:
- 0001127602-22-021110
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2022-08-16 17:04:08
- Reporting Period:
- 2022-08-15
- Accepted Time:
- 2022-08-16 17:04:08
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1492422 | Apellis Pharmaceuticals Inc. | APLS | Pharmaceutical Preparations (2834) | 271537290 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1773588 | J. Adam Townsend | C/O Apellis Pharmaceuticals, Inc. 100 Fifth Avenue, 3Rd Floor Waltham MA 02451 | Chief Commercial Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2022-08-15 | 12,500 | $15.09 | 55,407 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2022-08-15 | 12,500 | $69.00 | 42,907 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Option (Right to Buy) | Disposition | 2022-08-15 | 12,500 | $0.00 | 12,500 | $15.09 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 327,500 | 2028-11-15 | No | 4 | M | Direct |
Footnotes
- This is a scheduled exercise and sale form an established 10b5-1 plan.
- This represents a stock option granted 11/16/2018 that vest as to 25% of the shares underlying the options on the first anniversary of the grant, with the remaining 75% of the shares underlying the options vesting in equal monthly installments thereafter through the fourth anniversary of the grant, subject to continued service.
Billionaire Hedge Funds
